Clinical Trials on B-Cell Malignancies in Japan

Total 1009 results

AstraZeneca

Active, not recruiting

A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies

Part1: Advanced B-cell Malignancies | Part2: r/rCLL and r/rMCL | Part3: Untreated CLL

Japan
AstraZeneca
MedImmune LLC

Completed

A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies

Blood Cancer | Advanced B Cell Malignancies

Japan
Merck Sharp & Dohme LLC

Active, not recruiting

A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)

Mature B-cell Neoplasms

Japan
Otsuka Pharmaceutical Co., Ltd.

Active, not recruiting

A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

Relapsed or Refractory Diffuse Large B-cell Lymphoma

Japan
Mundipharma K.K.

Completed

Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies

Recurrent or Refractory T/NK-cell Malignancies

Japan
BeiGene

Active, not recruiting

Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

Mature B-cell Malignancies

Japan
Incyte Corporation

Recruiting

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

B-Cell Malignancies

United States, Spain, Belgium, Japan, Italy, France, United Kingdom, Israel, Turkey, Norway, Korea, Republic of, Czechia, Sweden, Austria, Poland, Hungary, Denmark
Sandoz
Novartis Pharmaceuticals

Completed

GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma

Indolent B-cell Non-Hodgkin's Lymphoma

Japan
Jichi Medical University
Takara Bio Inc.

Unknown

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Japan
Janssen Pharmaceutical K.K.
Pharmacyclics LLC.

Completed

A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms

Recurrent Mature B-cell Neoplasms

Japan
Eisai Co., Ltd.

Completed

A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Japan
AstraZeneca

Completed

Open Label, Dose Escalation Phase I Study of AZD2281

Advanced Solid Malignancies

Japan
AstraZeneca

Active, not recruiting

An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
AstraZeneca

Completed

A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients

Advanced Solid Malignancies

Japan
SymBio Pharmaceuticals

Completed

A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

Japan
AstraZeneca

Completed

A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
AstraZeneca

Completed

Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
AstraZeneca

Completed

Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055

Cancer | Solid Tumors | Advanced Solid Malignancies

Japan
AstraZeneca
MedImmune LLC

Completed

Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects

Cancer | Advanced Solid Malignancies

Japan
AstraZeneca

Active, not recruiting

Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
Gilead Sciences

Completed

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

Follicular Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Indolent Non-Hodgkin Lymphoma | Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia)

Japan
Pfizer
Hoffmann-La Roche

Recruiting

A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

Diffuse Large B-Cell Lymphoma

Taiwan, United States, Japan
Duke University

Active, not recruiting

Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B Cell Lymphoma

United States, Japan, Italy, Korea, Republic of, Czechia, Singapore
Genmab
AbbVie

Active, not recruiting

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL (EPCORE™ NHL-3)

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma

Japan
SymBio Pharmaceuticals

Completed

Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL

Diffuse Large B Cell Lymphoma

Japan
Novartis Pharmaceuticals

Recruiting

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

B-cell Non-Hodgkin Lymphoma (B-NHL) | B-cell Acute Lymphoblastic Leukemia (B-ALL)

Japan, Italy, Spain, Belgium, Singapore, France, Israel, United States
AstraZeneca

Terminated

Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine

Cancer | Solid Tumors | Advanced Solid Malignancies

Japan
GlaxoSmithKline

Completed

A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia

Leukaemia, Lymphoblastic

Japan
Novartis Pharmaceuticals

Completed

Phase I Study of PDR001 in Patients With Advanced Malignancies.

Advanced Malignancies

Japan
Incyte Corporation

Completed

A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)

Lymphoma

Japan
Incyte Biosciences Japan GK

Recruiting

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) (J-MIND)

Diffuse Large B-cell Lymphoma | Non Hodgkins Lymphoma

Japan
AstraZeneca

Recruiting

A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Follicular Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | B-cell Non Hodgkin Lymphoma

Korea, Republic of, United States, Japan, Taiwan, Australia
Novartis Pharmaceuticals

Active, not recruiting

Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies

Diffuse Large B-cell Lymphoma

Spain, Germany, Canada, Italy, Hong Kong, China, Japan, France, United States, Singapore
AbbVie

Recruiting

A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan

Chronic Lymphocytic Leukemia

Japan
AstraZeneca

Completed

Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies

Cancer | Advanced Solid Malignancies

Japan
AstraZeneca

Completed

Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient

Cancer | Advanced Solid Malignancies

Japan
GlaxoSmithKline

Completed

Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular

Japan
Kyowa Kirin Co., Ltd.

Active, not recruiting

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Japan
GlaxoSmithKline

Completed

A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic

Japan
Astellas Pharma Inc

Completed

Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors

Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies

Japan
Novartis Pharmaceuticals
Bristol-Myers Squibb

Recruiting

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

United States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
Pfizer
Incyte Corporation; MorphoSys AG

Recruiting

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

United States, Japan, Puerto Rico, Korea, Republic of
Mitsubishi Tanabe Pharma Corporation

Recruiting

A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

Diffuse Large B-Cell Lymphoma

Japan
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread

Advanced Malignancies

Japan
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)

Lymphoma, B-Cell

Japan
SymBio Pharmaceuticals

Completed

Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Low-grade B Cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated

Japan
SymBio Pharmaceuticals

Completed

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Follicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, Diffuse

Japan, Korea, Republic of
GlaxoSmithKline

Completed

A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic

Korea, Republic of, Japan
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients (JULIET)

Diffuse Large B-cell Lymphoma (DLBCL)

United States, Japan, Australia, Italy, Canada, Germany, Norway, Netherlands, France, Austria
SymBio Pharmaceuticals

Completed

Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Japan

Clinical Trials on B-Cell Malignancies in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations